| Immunocellular Therapeutics' Brain Cancer Vaccine Extends Survival Rate in Small Trial Douglas Cress submits:By vandersonA brain cancer vaccine from Immunocellular Therapeutics (IMUC.OB) has yielded positive results in a small Phase I clinical trial, reports Fierce Biotech. The study involved only 16 patients with glioblastoma multiforme, the most common form of brain cancer. The patients received the ICT-107 vaccine in combination with conventional treatments such as surgery and chemotherapy. Half of the group remained alive at 18 months with no progression of the disease, and 7 out of 16 patients remain alive with no disease progression at an average of 29 months. The overall patient survival rate was 100 percent at one year and 80 percent at two years, compared to a historical survival rate with standard therapy of 61.1 percent at one year and 26.5 percent at two years. ICT-107 is a dendritic cell-based vaccine that uses the patient’s own cells to provoke a disease-fighting response.Complete Story » seekingalpha.com |
unicef/kiwanis eliminate project - Video Kiwanis, UNICEF join forces to save 129 million mothers and newborns feedproxy.google.com |
Cord Blood America CEO Interview Details Company's 2010 Achievements (PR Newswire) Cord Blood America, Inc. said today that its co-founder and CEO, Matthew Schissler, reviewed the Company's progress in 2010, saying it is "on track" to accomplish all of its goals, in an interview with analyst Francis Gaskins. Â us.rd.yahoo.com |
Killing 'Superbugs' in Hospitals, Homes Researchers are trying to create antimicrobials to fight specific types of antibiotic-resistant bugs in the human body, on hospital walls and even on the roof of your house. online.wsj.com |
China Cord Blood Corporation Reports Second Quarter and First Half Fiscal 2011 Financial Results [PR Newswire] - China Cord Blood Corporation , China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced unaudited financial results for the second quarter and first half of fiscal 2011 ended September 30, 2010. us.rd.yahoo.com |